The global Alzheimer’s disease therapeutic market size is expected to grow by $3.99B, accelerating at a CAGR of 8.76% between 2021 and 2026, according to a report by Technavio. The report has considered various factors including the patient population, prevalence rate of Alzheimer's disease, revenue generated by vendors, and disposable income among others to estimate the size of the market.
The Alzheimer's disease therapeutics market is fragmented. The market has several approved therapeutics for the symptomatic treatment of Alzheimer's disease. The strong prevalence of the disease and the need for highly efficacious therapeutics are compelling several vendors to develop new vaccines. Besides, the strong pipeline of novel therapeutics is expected to pave the way for new entrants. Hence, the market is expected to witness the launch of various novel therapeutics and the entry of a few new players during the forecast period. This will intensify the competition in the market and encourage vendors to form strategic alliances to increase their product offerings and geographical reach.